Summary & Overview
HCPCS Level II A2033: Myriad morcells, 4 milligrams
HCPCS Level II code A2033 identifies a 4 milligram unit of Myriad morcells, a supply used as a device component in procedures involving tissue morcellation. Nationally, supply and device codes like A2033 matter because they affect facility billing lines, surgical supply cost reporting, and claims adjudication for outpatient and ambulatory surgery services. Facilities and billing teams rely on accurate HCPCS mapping to ensure proper identification of disposable surgical components and to support consistent reimbursement.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context and likely sites of service, standard payer coverage considerations, and the types of benchmarks and policy items typically reported for supply/device HCPCS codes. This publication also outlines common modifiers used with supply lines, notes where input data is missing, and highlights the operational implications for facility billing and supply cost tracking. The goal is to provide a clear reference for coding, billing reconciliation, and payor engagement regarding HCPCS Level II code A2033 in the national context.
Billing Code Overview
HCPCS Level II code A2033 describes Myriad morcells, 4 milligrams. This item is a unit of a surgical adjunct or device component supplied for procedures that require morcellation material in a 4 mg presentation. Service type: supply/device component for surgical procedures. Typical site of service: hospital outpatient department or ambulatory surgery center, where surgical instruments and disposables for tissue morcellation are used.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing a minimally invasive gynecologic or urologic operative procedure that requires tissue morcellation for specimen extraction. The operating surgeon prepares a sterile supply of A2033 Myriad morcells, 4 milligrams, which are small tissue fragmentation devices or adjunct pharmacologic agents used intraoperatively to facilitate morcellation or reduce bleeding during morcellation. The patient presentation may include symptomatic uterine fibroids, adnexal mass requiring removal, or benign pelvic masses where laparoscopic or robotic-assisted morcellation is planned. The clinical workflow: preoperative evaluation and informed consent; induction of general anesthesia in an ambulatory surgery center or hospital operating room; laparoscopic or robotic approach to remove target tissue; use of morcellation devices and adjuncts such as A2033 during specimen extraction; hemostasis and completion of procedure; postoperative monitoring in PACU and discharge when criteria met. Typical sites of service are the hospital outpatient department, ambulatory surgery center, or inpatient operating room depending on case complexity and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; only when no other modifier applies and payer accepts unspecified modifier. |